The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Oct 23,2020|By Liying Ma, Xing Bian & Wenchu Lin doi.org/10.1186/s13046-020-01728-2